Navigation Links
ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
Date:4/30/2009

EXTON, Pa., April 30 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends(R): Bone and Mineral Metabolism in Dialysis, a syndicated publication offering comprehensive insight into the management of calcium, phosphorus and PTH in dialysis patients. The report is based on actual patient and laboratory data collected in February 2009 from approximately 1,000 dialysis patient charts.

This ChartTrends(R) report sheds light on patient demographics, laboratory values, and treatment prevalence with phosphate binders, Nutritional Vitamin D, Active Vitamin D and Sensipar. Moreover, it provides information on the interplay between these therapies and uncovers actual (as opposed to self-reported) product dosing and titration, brand switching and reasons for switching, as well as brand persistency.

In the treatment of hyperphosphatemia, patients tend to be initiated on phosphate binder monotherapy when phosphorus reaches 5.7 mg/dL. Phosphorus levels are significantly higher when combination therapy is initiated. Contrary to what Nephrologists perceive based on self-reported data, combination binder therapy is prescribed infrequently. Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill burden. Shire's Fosrenol has the lowest pill burden, but significantly lower persistency compared to Renagel, Tums and FMC's PhosLo. Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half of the Renvela patients had been switched from Renagel.

The vast majority of dialysis patients are on Active Vitamin D formulations such as Abbott's Zemplar and Genzyme's Hectorol. The use of Nutritional Vitamin D (i.e. ergocalciferol) appears to be increasing and the concomitant use of Nutritional Vitamin D does have an impact on the dose of Active Vitamin D. Although the use of Active Vitamin D is widespread, a substantial number of patients are still above the target level for iPTH.

Amgen's Sensipar tends to be reserved for difficult to control patients and is initiated at a mean iPTH of 669 pg/mL, with more than one-quarter of patients being initiated when iPTH >750 pg/mL. Although MD perception is that treatment with Sensipar can result in lower doses of Vitamin D and phosphate binders, the converse is actually true. Patients treated with Sensipar tend to be on higher doses of both agents. Despite more aggressive therapy, a significant proportion of these patients remain uncontrolled.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New property found in ancient mineral lodestone
2. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
3. New insight to demineralization
4. Sea urchin yields a key secret of biomineralization
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
7. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
8. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
9. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
10. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):